-
公开(公告)号:EP4073105A1
公开(公告)日:2022-10-19
申请号:EP20817394.8
申请日:2020-12-08
申请人: Biotest AG
发明人: OTT, Vera , MÖLLER, Wolfgang , MANEG, Oliver
-
-
公开(公告)号:EP4039701A1
公开(公告)日:2022-08-10
申请号:EP20870789.3
申请日:2020-09-09
申请人: OSAKA UNIVERSITY
摘要: A method for producing a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel, the method comprising:
a step 1 of applying a fibrinogen solution containing at least one selected from the group consisting of cells and drugs and fibrinogen dropwise onto a surface of a substrate made of a gelatin hydrogel;
a step 2 of adding thrombin to the fibrinogen solution on the surface of the substrate;
a step 3 of placing a support film on and in contact with a top surface of the fibrinogen solution to which the thrombin has been added;
a step 4 of forming a fibrin sheet containing the at least one selected from the group consisting of cells and drugs in a fibrin gel between the substrate and the support film by a reaction between the fibrinogen and the thrombin; and
a step 5 of melting the substrate at a temperature not lower than a melting temperature of the gelatin hydrogel to separate, from the substrate, the fibrin sheet supported by the support film.-
公开(公告)号:EP3411022B1
公开(公告)日:2021-09-15
申请号:EP17748023.3
申请日:2017-01-31
IPC分类号: A61K9/50 , A61K9/62 , A61K38/36 , A61K38/37 , C07K14/75 , C07K14/745 , C07K14/755
-
公开(公告)号:EP3270950B1
公开(公告)日:2021-04-21
申请号:EP16713796.7
申请日:2016-03-21
-
公开(公告)号:EP3411022A2
公开(公告)日:2018-12-12
申请号:EP17748023.3
申请日:2017-01-31
申请人: Emory University , Georgia Tech Research Corporation , Chapman University , Children's Healthcare of Atlanta, Inc.
IPC分类号: A61K9/50 , A61K9/62 , A61K38/36 , A61K38/37 , C07K14/75 , C07K14/745 , C07K14/755
CPC分类号: A61K9/5073 , A61K9/0019 , A61K9/5052 , A61K9/5089 , A61K38/37
摘要: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
-
公开(公告)号:EP3404037A1
公开(公告)日:2018-11-21
申请号:EP17738641.4
申请日:2017-01-12
发明人: KIM, Jun Sic , KIM, Hyo Jin , PARK, Ji Yoon , LEE, Ju Ho , SON, Jae Woon , SHIN, Yong Won
摘要: The present disclosure relates to a method for purifying fibrinogen, and more particularly to a method for purifying fibrinogen, comprising the steps of: (a) precipitating fibrinogen of a fibrinogen-containing solution by adding glycine to the solution for a concentration of glycine to be 1.5 to 2.5M, and then removing a supernatant and recovering a precipitate (1 st glycine precipitation); (b) dissolving the precipitate of 1 st glycine precipitation of step (a) in a dissolution buffer to obtain a solution, precipitating the solution by adding glycine thereto for a concentration of glycine to be 0.2 to 1.2M, and recovering a supernatant (2 nd glycine precipitation); (c) precipitating the supernatant of step (b) by adding glycine thereto for a concentration of glycine to be 1.5 to 2.5M, and recovering a precipitate (3 rd glycine precipitation); and (d) dissolving the precipitate of step (c) in a dissolution buffer to obtain a solution, and subjecting the solution to nanofiltration (NF) using a nanofilter.
The novel method for purifying fibrinogen protein according to the present disclosure is a highly safe method that fundamentally blocks the entry of viruses. Furthermore, it can purify fibrinogen protein with high purity and high recovery rate by a simple process, and thus is very economical and efficient. In addition, fibrinogen purified by the method of the present disclosure has an advantage over fibrinogen purified by a conventional method in that it has higher purity, and thus has increased local activity, indicating that it can be effectively used for the prevention and treatment of blood-related diseases, particularly blood clotting diseases.-
公开(公告)号:EP3362473A1
公开(公告)日:2018-08-22
申请号:EP16784956.1
申请日:2016-10-14
IPC分类号: C07K14/75 , G01N33/574
CPC分类号: G01N33/57423 , A21D8/04 , A61K38/363 , C07K14/75 , C12N9/2414 , C12Y302/01133 , G01N33/5076 , G01N33/574
摘要: The present invention relates to the use of a fibrinogen capture agent or a fibrinogen detection agent in an assay to detect a Ciz1 b-variant.
-
公开(公告)号:EP2277912B1
公开(公告)日:2016-09-28
申请号:EP10184552.7
申请日:2005-06-07
IPC分类号: C07K14/81 , C07K14/76 , C07K14/75 , C07K14/755 , C07K14/47 , C07K1/16 , B01D15/08 , B01D15/20 , B01D15/42
CPC分类号: B01D15/08 , B01D15/206 , B01D15/424 , C07K1/16 , C07K14/47 , C07K14/75 , C07K14/755 , C07K14/76 , C07K14/79 , C07K14/81 , C07K16/00
-
公开(公告)号:EP1885487B1
公开(公告)日:2016-03-23
申请号:EP06727057.9
申请日:2006-05-09
发明人: BETLEY, Jason, Richard , PEARSON, James, Christopher , BEACOM, Ben, Martin , PODGORSKI, Tadeusz, Antoni , PANNELL, Robert, William
IPC分类号: B01J20/32 , G01N30/00 , G01N33/86 , C07K14/75 , C07D251/50 , B01J20/286 , B01J20/289 , C07D251/48
CPC分类号: C07D251/48 , B01J20/286 , B01J20/289 , B01J20/3212 , B01J20/3219 , B01J20/3248 , B01J20/3251 , B01J20/3253 , B01J20/3255 , B01J2220/54 , B01J2220/58 , C07K14/75 , G01N33/86
-
-
-
-
-
-
-
-
-